Skip to main content
SpringerLink
Log in

PET and PET/CT in Thyroid Cancer

  • Chapter
PET in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 170))

Abstract

Thyroid cancer can be divided into three main groups: tumors with follicle cell differentiation (differentiated thyroid cancer), tumors with C-cell differentiation (medullary thyroid cancer), and anaplastic carcinomas. The insular carcinoma takes an intermediate place between differentiated and anaplastic cancer. Within the category of differentiated cancers, a distinction is made between papillary and follicular tumors. Papillary tumors are found most frequently and several subtypes are defined referring to tumor capsule invasion, the extent of invasion, the presence of sclerosis and oncocytic or oxyphil cells. The last subtype is also called Hürthle-cell carcinoma and is of critical importance because iodine uptake is often low or completely missing. C-cell cancer can develop spontaneously or be genetically determined as familial medullary cancer or in a multiple endocrine neoplasia (MEN-2a/ MEN-2b).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akslen LA (1993) Prognostic importance of histologie grading in papillary thyroid carcinoma. Cancer 72:2680–2685

    Article  PubMed  CAS  Google Scholar 

  2. Brandt-Mainz K, Müller SP, Gorges R, Sailer B, Bockisch A (2000) The value of fluorine-18 fluoro-deoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 27:490–496

    Article  PubMed  CAS  Google Scholar 

  3. Briele B, Hotze A, Kropp J, Bockisch A, Overbeck B, Grunwald F, Kaiser W, Biersack HJ. A comparison of 201T1 and 99mTc-MIBI in the follow-up of differentiated thyroid carcinomas (in German). Nuklearmedizin 30:115–124

    Google Scholar 

  4. Chung JK, So Y, Lee JS et al (1999) Value of FDG PET in papillary thyroid carcinoma with negative 1-131 whole-body scan. J Nucl Med 40:986–992

    PubMed  CAS  Google Scholar 

  5. Dai G, Levy O, Carrasco N (1996) Cloning and characterization of the thyroid iodide transporter. Nature 379:458–460

    Article  PubMed  CAS  Google Scholar 

  6. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grunwald F (2001) Fluorine-18 fluorode-oxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28:1671–1676

    Article  PubMed  CAS  Google Scholar 

  7. Dietlein M, Scheidhauer K, Voth E et al (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigra-phy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24:1342–1348

    Article  PubMed  CAS  Google Scholar 

  8. Feine U, Lietzenmayer R, Hanke JP et al (1996) Fluo-rine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37:1468–1472

    PubMed  CAS  Google Scholar 

  9. Gallowitsch HJ, Kresnik E, Mikosch P, Pipam W, Gomez I, Lind P (1996) Tc-99m-tetrofosmin scintig-raphy: an alternative scintigraphic method for following up differentiated thyroid carcinoma-preliminary results. Nuklearmedizin 35:230–235

    PubMed  CAS  Google Scholar 

  10. Gilliland FD, Hunt WC, Morris DM et al (1997) Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564–573

    Article  PubMed  CAS  Google Scholar 

  11. Grebe SK, Hay ID (1996) Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 5:43–63

    PubMed  CAS  Google Scholar 

  12. Grünwald F, Ruhlmann J, Ammari B, Knopp R, Hotze A, Biersack HJ (1988) Experience with a high-dose therapy concept in metastatic differentiated thyroid cancer (in German). Nuklearmedizin 27:266–271

    PubMed  Google Scholar 

  13. Grünwald F, Schomburg A, Bender H et al (1996) Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23:312–319

    Article  PubMed  Google Scholar 

  14. Grünwald F, Menzel C, Bender H et al (1997) Comparison of F-18 FDG-PET with iodine-131 and Tc-99m-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7:327–335

    Article  PubMed  Google Scholar 

  15. Grünwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, Risse J, Biersack HJ (1998) Redifferentia-tion therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39:1903–1906

    PubMed  Google Scholar 

  16. Hay ID, Grant CS, Bergstralh EJ et al (1998) Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 124:958–964

    PubMed  CAS  Google Scholar 

  17. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500–2507

    Article  PubMed  Google Scholar 

  18. Matthaei S, Trost B, Hamann A, Kausch C, Benecke H, Greten H, Hoppner W, Klein HH (1995) Effect of in vivo thyroid hormone status on insulin signalling and GLUT1 and GLUT4 glucose transport systems in rat adipocytes. J Endocrinol 144:347–357

    Article  PubMed  CAS  Google Scholar 

  19. Menzel C, Grunwald F, Schomburg A, Palmedo H, Bender H, Spath G, Biersack HJ (1996) “High-dose“ radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 37:1496–1503

    PubMed  CAS  Google Scholar 

  20. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K, Hahn K (2000) Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41:1989–1995

    PubMed  CAS  Google Scholar 

  21. Nemec J, Nyvltova O, Blazek T, Vlcek P, Racek P, Novak Z, Preiningerova M, Hubackova M, Krizo M, Zimak J, Bilek R (1996) Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 23:69–71

    Article  PubMed  CAS  Google Scholar 

  22. Palmedo H, Hensel J, Reinhardt M, Von Mallek D, Matthies A, Biersack HJ (2002) Breast cancer imaging with PET and SPECT agents: an in vivo comparison. Nucl Med Biol 29:809–815

    Article  PubMed  CAS  Google Scholar 

  23. Palmedo H, Bucerius J, Joe A, Strunk H, Hording N, Meyka S, Roedel R, Wolff M, Wardelmann E, Biersack HJ, Jaeger U (2006) Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47:616–624

    PubMed  Google Scholar 

  24. Reiners C (1993) Radiojodtherapie-Indikation, Durchführung und Risiken. Dtsch Ärztebl 90:2217–2221

    Google Scholar 

  25. Reske SN, Kotzerke J (2001) FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, “Onko-PET III“, 21 July and 19 September 2000. Eur J Nucl Med 28:1707–1723

    Article  PubMed  CAS  Google Scholar 

  26. Schlumberger M, Challeton C, De Vathaire F et al (1996) Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598–605

    PubMed  CAS  Google Scholar 

  27. Scott GC, Meier DA, Dickinson CZ (1995) Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide. J Nucl Med 36:1843–1845

    PubMed  CAS  Google Scholar 

  28. Simon D (1997) Von limitierter bis erweiterter Radikalität der Operation beim Schilddrüsenkarzinom. In: Roth et al (eds) Klinische Onkologie. Huber, Bern, pp 347–357

    Google Scholar 

  29. Simon D, Goretzki PE, Witte J, Roher HD (1996) Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. World J Surg 20:860–866

    Article  PubMed  CAS  Google Scholar 

  30. Sisson JC, Ackermann RJ, Meyer MA, Wahl RL (1993) Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 77:1090–1094

    Article  PubMed  CAS  Google Scholar 

  31. Sisson JC, Giordano TJ, Jamadar DA, Kazerooni EA, Shapiro B, Gross MD, Zempel SA, Spaulding SA (1996) 131-1 treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer 78:2184–2192

    Article  PubMed  CAS  Google Scholar 

  32. Sobin LH, Wittekind C (2002) TNM classification of malignant tumours, 6th edn. Wiley, New York, p 52

    Google Scholar 

  33. Stewart BW, Kleihues P (2003) Thyroid cancer. In: Stewart BW, Kleihues P (eds) World cancer report. IARC Press, Lyon, pp 257–260

    Google Scholar 

  34. Van Toi KM, Jager PL, Piers DA, Pruim J, de Vries EG, Dullaart RP, Links TP (2002) Better yield of (18)fluo-rodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 12:381–387

    Article  Google Scholar 

  35. Vassilopoulou-Sellin R, Schultz PN, Haynie TP (1996) Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 78:493–501

    Article  PubMed  CAS  Google Scholar 

  36. Wang W, Macapinlac H, Larson SM et al (1999) [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291–2302

    Article  PubMed  CAS  Google Scholar 

  37. Wang W, Larson SM, Fazzari M et al (2000) Prognostic value of F-18 fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107–1113

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikums Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany

    H. Palmedo & M. Wolff

Authors
  1. H. Palmedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Nuklearmedizin, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany

    Stefan Dresel

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Palmedo, H., Wolff, M. (2008). PET and PET/CT in Thyroid Cancer. In: Dresel, S. (eds) PET in Oncology. Recent Results in Cancer Research, vol 170. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-31203-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-31203-1_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31202-4

  • Online ISBN: 978-3-540-31203-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation